Literature DB >> 27000263

Development of a tree shrew metabolic syndrome model and use of umbilical cord mesenchymal stem cell transplantation for treatment.

Xing-Hua Pan1,2,3, Lu Zhu1,2,3, Xiang Yao1,2,3, Ju-Fen Liu1,2,3, Zi-An Li1,2,3, Jian-Yong Yang1,2,3, Rong-Qing Pang1,2,3, Guang-Ping Ruan4,5,6.   

Abstract

The aim of this study was to establish a tree shrew metabolic syndrome model and demonstrate the utility of MSCs in treating metabolic syndrome. We used tree shrew umbilical cord mesenchymal stem cell (TS-UC-MSC) transplantation for the treatment of metabolic syndrome to demonstrate the clinical application of these stem cells and to provide a theoretical basis and reference methods for this treatment. Tree shrew metabolic syndrome model showed significant insulin resistance, high blood sugar, lipid metabolism disorders, and hypertension, consistent with the diagnostic criteria. TS-UC-MSC transplantation at 16 weeks significantly reduced blood sugar and lipid levels, improved insulin resistance and the regulation of insulin secretion, and reduced the expression levels of the pro-inflammatory cytokines IL-1 and IL-6 (P < 0.05). The transplanted TS-UC-MSCs targeted the liver, kidney and pancreas; reduced liver cell degeneration, necrosis, and inflammatory exudation; mitigated bleeding congestion and inflammatory cell infiltration in the kidney; and reduced islet cell degeneration and necrosis. We successfully developed a tree shrew metabolic syndrome model and showed that MSC migrate in diseased organs and can attenuate metabolic syndrome severity in a tree shrew model.

Entities:  

Keywords:  Cell transplantation; Metabolic syndrome model; Treatment; Tree shrew; Umbilical cord mesenchymal stem cell

Year:  2016        PMID: 27000263      PMCID: PMC5101316          DOI: 10.1007/s10616-016-9966-1

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  29 in total

Review 1.  Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Authors:  Mohamed Asrih; François R Jornayvaz
Journal:  Mol Cell Endocrinol       Date:  2015-02-24       Impact factor: 4.102

Review 2.  Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence?

Authors:  Raphael P H Meier; Yannick D Müller; Philippe Morel; Carmen Gonelle-Gispert; Leo H Bühler
Journal:  Stem Cell Res       Date:  2013-08-29       Impact factor: 2.020

Review 3.  Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux.

Authors:  Carlos G Santos-Gallego; Chiara Giannarelli; Juan José Badimón
Journal:  Curr Atheroscler Rep       Date:  2011-06       Impact factor: 5.113

Review 4.  Large artery stiffness: implications for exercise capacity and cardiovascular risk.

Authors:  Bronwyn A Kingwell
Journal:  Clin Exp Pharmacol Physiol       Date:  2002-03       Impact factor: 2.557

5.  Pancreatic islet-like clusters from bone marrow mesenchymal stem cells of human first-trimester abortus can cure streptozocin-induced mouse diabetes.

Authors:  Yihua Zhang; Wenzheng Shen; Jinlian Hua; Anmin Lei; Changrong Lv; Huayan Wang; Chunrong Yang; Zhimin Gao; Zhongying Dou
Journal:  Rejuvenation Res       Date:  2011-01-04       Impact factor: 4.663

6.  Serum ferritin, insulin resistance, and metabolic syndrome: clinical and laboratory associations in 769 non-hispanic whites without diabetes mellitus in the HEIRS study.

Authors:  Ronald T Acton; J Clayborn Barton; James C Barton
Journal:  Metab Syndr Relat Disord       Date:  2014-11-25       Impact factor: 1.894

7.  Association of homeostasis model assessment of insulin resistance, adiponectin, and low-grade inflammation with the course of the metabolic syndrome.

Authors:  YuSong Ding; ShuGang Li; Ru-Lin Ma; Heng Guo; JingYu Zhang; Mei Zhang; JiaMing Liu; ShuXia Guo
Journal:  Clin Biochem       Date:  2015-02-17       Impact factor: 3.281

8.  Stem cell therapy to treat diabetes mellitus.

Authors:  Chee Gee Liew; Peter W Andrews
Journal:  Rev Diabet Stud       Date:  2009-02-10

9.  Prevention of atherosclerosis in LDL receptor-mutant mice by human umbilical cord blood cells.

Authors:  Norman Ende; Milton Ende; Ruifeng Chen; Kathleen Coakley; Alluru S Reddi
Journal:  Res Commun Mol Pathol Pharmacol       Date:  2005

Review 10.  Mesenchymal stem cells: biology and clinical potential in type 1 diabetes therapy.

Authors:  Meng Liu; Zhong Chao Han
Journal:  J Cell Mol Med       Date:  2008-02-24       Impact factor: 5.310

View more
  2 in total

1.  Establishment of Neurobehavioral Assessment System in Tree Shrew SCT Model.

Authors:  Yang-Yang Wang; Jie-Dong Wang; Lei Wang; Qi-Qin Dan; Qing-Jie Xia; Ting-Hua Wang; Liu-Lin Xiong
Journal:  J Mol Neurosci       Date:  2019-12-16       Impact factor: 3.444

2.  Human umbilical cord-derived mesenchymal stem cells ameliorate insulin resistance by suppressing NLRP3 inflammasome-mediated inflammation in type 2 diabetes rats.

Authors:  Xiaoya Sun; Haojie Hao; Qingwang Han; Xiaoyan Song; Jiejie Liu; Liang Dong; Weidong Han; Yiming Mu
Journal:  Stem Cell Res Ther       Date:  2017-11-02       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.